BusinessDaiichi Sankyo and ArQule Announce Continuation of METIV-HCC Phase 3 Study of Tivantinib in Second-Line Hepatocellular CarcinomaBy Nasdaq OMXMar 22, 2016, 11:30 AM UTC
BusinessArQule Presents Clinical Biomarker Data From Phase 2 Study and Ongoing Phase 3 METIV-HCC Study of Tivantinib in Second-Line Hepatocellular Carcinoma at the 2016 Gastrointestinal Cancers SymposiumBy Nasdaq OMXJan 25, 2016, 12:31 PM UTC
BusinessArQule Presents Clinical Biomarker Data From Phase 2 Study and Ongoing Phase 3 METIV-HCC Study of Tivantinib in Second-Line Hepatocellular Carcinoma at the 2016 Gastrointestinal Cancers SymposiumBy Nasdaq OMXJan 25, 2016, 12:31 PM UTC
